Our lead drug candidate SDX-7320 is in pre-clinical development, and has demonstrated broad biologic activity, including cytostasis and anti-metastasis. The mechanism of action is not completely understood, but independent research suggests that it may also benefit from an anti-proliferative effect, in addition to these other effects.
Recent understandings from multiple premier researchers worldwide have shed light on the fact that cancer cells have redundant, compensatory survival systems to ensure their proliferation. Other recent findings have proven that tumors create unique, ideal environments for growth. Therefore, in order to completely eliminate a tumor, existing cells must be destroyed and the environment must be returned to its normal state.
Current therapies need drugs with complementary, broad-based activity. The current thinking is to use combination therapy to achieve a lasting result. Economic pressures may limit the number of compounds that can be prescribed, forcing doctors to make tough decisions.
Our compound is known to have the necessary broad spectrum activity to shut down the tumor’s ability to proliferate and stop the compensatory survival system, providing the best cost-benefit return. Other benefits include the fact that drug-drug interactions are minimized, and clinical costs to determine which combinations work best are greatly reduced.